ACTO Secures $18M Financing to Accelerate Growth and Strengthen Position as #1 Learning Platform in Life Sciences
TORONTO, July 07, 2022 (GLOBE NEWSWIRE) -- ACTO, the omnichannel learning and enablement platform for life sciences, today announced the closing of a US$18 million equity financing. The investment was led by Questa Capital, a healthcare venture growth equity firm that actively invests in healthcare and life sciences software. With this investment, Questa joins ACTO's existing investors: Resolve Growth Partners, Salesforce Ventures, Panache Ventures, and MaRS Investment Accelerator Fund1.
This investment by Questa Capital validates the large market opportunity to transform critical learning experiences and sales enablement approaches in the life sciences industry. The company will use the proceeds of the investment to accelerate the growth and scale of ACTO and explore potential business and partnership opportunities.
“The rapid growth of our customer community demonstrates the industry’s interest and hunger for a new way of delivering commercial learning and development. Trends driving this shift include the increase in clinical data and the demand for flexible access to information in the flow of work. We are happy to meet these needs with the only omnichannel learning platform for the life sciences industry,” says Parth Khanna, CEO of ACTO. He added, “We are thrilled to have Questa Capital join us on this journey and look forward to delighting our customers with innovative solutions, such as our recently announced conversational assistant LAICA™, to make commercial learning in Life Sciences easier and more engaging.”
ACTO is disrupting the learning experience and sales enablement landscape in life sciences, which is primed for a new, modern and user-accessible solution to training and enabling learners in pharma. This round of funding allows ACTO to expand and enhance capabilities to accelerate its technology as the #1 life sciences-focused learning enablement platform.
“At Questa, we are passionate about investing in innovative and well-positioned companies that empower the healthcare and life sciences industries to improve patient outcomes. We are excited to partner with Parth and the outstanding management team at ACTO to invest in the company’s strategic growth plan. With experienced leadership and cutting-edge SaaS technology, ACTO is serving a market ripe for a better approach,” says Ryan Drant, Founder and Managing Partner at Questa Capital, who was recently recognized as a top healthcare investor of 2022 by GrowthCap Advisory2.
The current financing brings ACTO's total invested capital to more than US$30 million. ACTO continues to experience robust user and revenue growth, including a 500% increase in annual recurring revenue since 2018.
About ACTO
Global life science companies rely on ACTO's AI-powered SaaS platform to transform their field teams’ learning journey and experience at scale. Commercial and clinical leaders leverage ACTO's omnichannel learning platform to educate and engage learners through unified educational experiences across the care continuum. Building an ecosystem for life sciences, ACTO maintains a network of partnerships with content agencies, data providers, technology companies, and more. To learn more about ACTO, please visit acto.com.
For media inquiries or to request a media interview, please contact:
Swati Mehta, Account Director
PR Associates
smehta@prassociates.com
403-804-0768
About Questa Capital
Questa Capital is a venture growth equity firm focusing on investments in expansion-stage healthcare companies. Questa seeks out disruptive, technology-enabled business models that help improve patient lives, streamline market inefficiencies, and provide better quality care. The firm partners with superior management teams to help build innovative market leaders in the healthcare technology, services and medical devices sectors. Questa is led by industry veterans in healthcare investment and operations who have invested in and advised more than 50 growth-stage companies. More information is available at www.questacapital.com.
- https://www.acto.com/newsroom/acto-closes-11-5m-series-a-round-to-accelerate-virtual-transformation-for-life-sciences-companies/
- https://www.questacapital.com/questa-managing-partners-honored-as-top-25-healthcare-investors-in-2022/
Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/39e47304-b45b-4459-bd98-c29fe7f75e3f
https://www.globenewswire.com/NewsRoom/AttachmentNg/a1b2304b-a3c1-4d77-9ab6-121918aea911
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of Directors18.4.2024 17:46:00 CEST | Press release
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of Directors Increase in the dividend from CHF 2.90 to CHF 3.00 per share Monica Manotas elected as additional independent member of the Board of DirectorsLukas Braunschweiler, Myra Eskes, Oliver Fetzer, Matthias Gillner, Karen Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of the Board of DirectorsLukas Braunschweiler confirmed by shareholders as Chair of the BoardMyra Eskes, Oliver Fetzer, Christa Kreuzburg and Daniel R. Marshak confirmed as members of the Compensation CommitteeVarious amendments to the Articles of Incorporation approvedAll proposals relating to compensation approvedApproval of the Report on Non-Financial Matters 2023 (Sustainability Report) Männedorf, Switzerland, April 18, 2024 – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) endorsed all motions proposed by the Board of Directors. Shareholders approved the Annual Report, the
Ipsos: Continued momentum in Q118.4.2024 17:45:30 CEST | Press release
Continued momentum in Q1 Total growth: 4.8% Organic growth: 4.5% Paris, 18 April 2024 – Ipsos, one of the world’s leading market research companies, achieves a solid first quarter, with a revenue of €557.5m. Revenue (€m)20242023202220212020Q1557.5532.0547.8466.3428.7Q2555.1 574.0527.0357.3Q3588.0 601.5526.3468.6Q4714.7 682.1627.1582.9Total2,389.82,405.32,146.71,837.4 This income level confirms the continuation of the Group’s sustained growth. First-quarter growth stands at 4.8%, including 4.5% organic growth, 2.7% scope effect, and -2.4% of adverse currency effects. Ben Page, CEO of Ipsos, states: “The start of the year is encouraging. It demonstrates our ability to deliver sustainable solid growth combined with a high level of operating margin. Our geographical and sectoral diversity, which provides greater resilience, combined with the talent of our 20,000 employees, are major advantages for continuing our development. In a geopolitical environment that remains uncertain, we confirm
Q1 2024 Trading Statement18.4.2024 17:40:47 CEST | Press release
COMPANY ANNOUNCEMENT NO 12/2024 - April 18, 2024 Strong business momentum continued into 2024 – organic EBIT growth guidance raised Statement by Royal Unibrew’s CEO, Lars Jensen: “The first quarter has marked a strong start to the year. The business momentum we built throughout 2023 has continued into 2024. The continued strong performance of our markets in Northern Europe, combined with a normalized Italian On-Trade beer channel and a strong rebound in our International segment, drove solid organic volume growth of 6% in the first quarter. Strong value management efforts from our organization across all categories ensured organic net revenue growth of 10% in the first quarter. Going into 2024, we further intensified our focus on delivering the efficiency improvements after some turbulent years with unprecedented high inflation, strong volume growth and a series of acquisitions. This increased focus starts to yield results towards the end of the first quarter. Vrumona has now begun pro
Sdiptech AB (publ) - Notice of annual general meeting 202418.4.2024 17:40:00 CEST | Press release
Press release 18 April 2024, 17:40 NOTICE OF ANNUAL GENERAL MEETING 2024 OF SDIPTECH AB (PUBL) The shareholders of Sdiptech AB (publ), reg. no. 556672-4893 (the "Company") are hereby convened to the Annual General Meeting on 22 May 2024, at IVA (Royal Swedish Academy of Engineering Sciences), Grev Turegatan 16, 114 46 i Stockholm. The Board has decided, with the support of § 12 of the Company's Articles of Association, that those shareholders who are unable or unwilling to physically participate in the meeting shall be able to submit their votes in advance by so-called postal voting. More information about it below. General requirements for participation Shareholders who wish to participate in the meeting, regardless of whether this is done physically or by postal vote, must be entered in the share register kept by Euroclear Sweden AB as of the record date, 14 May 2024. Shareholders with nominee-registered shares must temporarily have the shares re-registered in their own name as of th
Sdiptech AB (publ) - Kallelse till årsstämma 202418.4.2024 17:40:00 CEST | Pressemelding
Pressmeddelande 18 april 2024, 17:40 KALLELSE TILL ÅRSSTÄMMA 2024 I SDIPTECH AB (PUBL) Aktieägarna i Sdiptech AB (publ), org. nr 556672-4893 (”Bolaget”), kallas härmed till årsstämma den 22 maj 2024 klockan 16.00, på IVA (Ingenjörsvetenskapsakademien), Grev Turegatan 16, 114 46 i Stockholm. Styrelsen har beslutat, med stöd av § 12 i Bolagets bolagsordning, att de aktieägare som inte kan eller vill delta fysiskt vid stämman ska kunna skicka in sina röster i förväg genom så kallad poströstning. Mer information om det nedan. Generellt krav för deltagande Aktieägare som önskar delta i stämman, oavsett om så sker fysiskt eller genom poströstning, måste vara upptagen i den av Euroclear Sweden AB förda aktieboken per avstämningsdagen den 14 maj 2024. Aktieägare med förvaltarregistrerade aktier måste tillfälligt låta omregistrera aktierna i eget namn per avstämningsdagen och kontakt bör tas med banken/förvaltaren i god tid innan. Förvaltaren har möjlighet att göra sådan rösträttsregistrering r